Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia

Leuk Lymphoma. 2022 Feb;63(2):503-505. doi: 10.1080/10428194.2021.1973673. Epub 2021 Nov 2.

Authors

Caspar da Cunha-Bang¹, Nikolai S Kirkby², Lennart Friis-Hansen^{3

4}, Carsten U Niemann^{1

4}

Affiliations

¹ Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
² Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.
³ Department of Clinical Biochemistry, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
⁴ Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark.

PMID: 34727829
DOI: 10.1080/10428194.2021.1973673

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Viral
BNT162 Vaccine*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
RNA, Messenger / genetics
Vaccination

Substances

Antibodies, Viral
RNA, Messenger
BNT162 Vaccine